W Wolfgang Fleischhacker
Overview
Explore the profile of W Wolfgang Fleischhacker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
202
Citations
3817
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Slot M, Urquijo Castro M, Rossum I, van Hell H, Dwyer D, Dazzan P, et al.
Schizophrenia (Heidelb)
. 2024 Oct;
10(1):89.
PMID: 39375356
Several multivariate prognostic models have been published to predict outcomes in patients with first episode psychosis (FEP), but it remains unclear whether those predictions generalize to independent populations. Using a...
2.
Luykx J, Visscher R, Rossum I, Waters P, de Witte L, Fleischhacker W, et al.
Lancet Psychiatry
. 2024 Sep;
11(10):828-838.
PMID: 39300641
Background: Antibodies against the N-methyl-D-aspartate receptor (NMDAR) have been described in the serum of people with schizophrenia spectrum disorders (schizophrenia). However, the prevalence and clinical relevance of these antibodies in...
3.
Siafis S, Brandt L, McCutcheon R, Gutwinski S, Schneider-Thoma J, Bighelli I, et al.
Lancet Psychiatry
. 2023 Dec;
11(1):36-46.
PMID: 38043562
Background: There is no consensus on defining relapse in schizophrenia, and scale-derived criteria with unclear clinical relevance are widely used. We aimed to develop an evidence-based scale-derived set of criteria...
4.
Fleischhacker W, Rossum I, Kahn R
Lancet Psychiatry
. 2023 Jun;
10(7):482-483.
PMID: 37353257
No abstract available.
5.
Rossum I, Weiser M, Galderisi S, Leucht S, Bitter I, Glenthoj B, et al.
Lancet Psychiatry
. 2023 Jan;
10(3):197-208.
PMID: 36716759
Background: Schizophrenia is a severe psychiatric disorder with periods of remission and relapse. As discontinuation of antipsychotic medication is the most important reason for relapse, long-term maintenance treatment is key....
6.
Jaywant A, Aulitzky W, Avari J, Buchheim A, Dubin M, Galffy M, et al.
Neuropsychiatr
. 2023 Jan;
37(3):115-121.
PMID: 36600105
Background: The coronavirus disease 2019 (COVID-19) pandemic has resulted in significant upheaval in psychiatric care. Despite survey data collected from psychiatric patients and broad samples of individuals in single countries,...
7.
Arango C, Buitelaar J, Correll C, Diaz-Caneja C, Figueira M, Fleischhacker W, et al.
Eur Neuropsychopharmacol
. 2022 May;
59:45-55.
PMID: 35550205
Schizophrenia is a severely debilitating neurodevelopmental disorder that requires continuous multidisciplinary treatment. Early onset schizophrenia (EOS, onset before 18) is associated with poorer outcomes than the adult-onset type. The transition...
8.
Dollfus S, Mucci A, Giordano G, Bitter I, Austin S, Delouche C, et al.
Front Psychiatry
. 2022 Feb;
13:826465.
PMID: 35173641
Background: Negative symptoms are usually evaluated with scales based on observer ratings and up to now self-assessments have been overlooked. The aim of this paper was to validate the Self-evaluation...
9.
Fleischhacker W, Podhorna J, Groschl M, Hake S, Zhao Y, Huang S, et al.
Lancet Psychiatry
. 2021 Feb;
8(3):191-201.
PMID: 33610228
Background: Cognitive impairment associated with schizophrenia predicts poor functional outcomes, but currently no approved pharmacotherapy is available. This study investigated whether the glycine transporter-1 inhibitor BI 425809 improves cognition in...
10.
Johnsen E, Kroken R, Loberg E, Rettenbacher M, Joa I, Larsen T, et al.
Lancet Psychiatry
. 2020 Oct;
7(11):945-954.
PMID: 33069317
Background: Amisulpride, aripiprazole, and olanzapine are first-line atypical antipsychotics that have not previously been compared head-to-head in a pragmatic trial. We aimed to compare the efficacy and safety of these...